ABATACEPT CONFERS CLINICAL EFFICACY REGARDLESS OF BASELINE CRP STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN THE AIM TRIAL

被引：0

作者：

Sibilia, Jean ^{[1
]}

Flipo, Rene Marc ^{[2
]}

Combe, Bernard ^{[3
]}

Gaillez, Corine ^{[4
]}

Le Bars, Manuela ^{[4
]}

Poncet, Coralie ^{[5
]}

Elegbe, Ayanbola ^{[6
]}

Westhovens, Rene ^{[7
]}

机构：

[1] Univ Strasbourg, Dept Rheumatol, Strasbourg, France

[2] Ctr Hosp Univ France, Dept Rheumatol, Lille, France

[3] Hop Lapeyronie, Montpellier, France

[4] Bristol Myers Squibb Co, Med Affairs, Rueil Malmaison, France

[5] Docs Int, Dept Biostat, Sevres, France

[6] Bristol Myers Squibb Co, Global Biometr Sci, Princeton, NJ USA

[7] Univ Hosp Gasthuisberg, Dept Rheumatol, Louvain, Belgium

来源：

RHEUMATOLOGY | 2012年 / 51卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：124 / 125

页数：2

共 50 条

[31] Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients [J].

Takahashi, Nobunori ;

Kojima, Toshihisa ;

Terabe, Kenya ;

Kaneko, Atsushi ;

Kida, Daihei ;

Hirano, Yuji ;

Fujibayashi, Takayoshi ;

Yabe, Yuichiro ;

Takagi, Hideki ;

Oguchi, Takeshi ;

Miyake, Hiroyuki ;

Kato, Takefumi ;

Fukaya, Naoki ;

Ishikawa, Hisato ;

Hayashi, Masatoshi ;

Tsuboi, Seiji ;

Kato, Daizo ;

Funahashi, Koji ;

Matsubara, Hiroyuki ;

Hattori, Yosuke ;

Hanabayashi, Masahiro ;

Hirabara, Shinya ;

Yoshioka, Yutaka ;

Ishiguro, Naoki .

MODERN RHEUMATOLOGY, 2013, 23 (05) :904-912

[32] Abatacept improves clinical responses regardless of baseline physical function: Results from the AIM trial. [J].

Russell, A ;

Emery, P ;

Kafka, SP ;

Aranda, R ;

Becker, JC ;

Mokliatchouk, O ;

Westhovens, R .

ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :S543-S543

[33] ABATACEPT OR INFLIXIMAB FOR PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: A TRIAL-BASED AND REAL-LIFE COST-CONSEQUENCE ANALYSIS [J].

Benucci, M. ;

Stam, W. ;

Gilloteau, I ;

Crocchiolo, D. ;

Sennfaelt, K. ;

Leclerc, A. ;

Bengtsson, N. ;

Maetzel, A. ;

Lucioni, C. .

VALUE IN HEALTH, 2011, 14 (07) :A307-A307

[34] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies [J].

Hirabara, Shinya ;

Takahashi, Nobunori ;

Fukaya, Naoki ;

Miyake, Hiroyuki ;

Yabe, Yuichiro ;

Kaneko, Atsushi ;

Ito, Takayasu ;

Oguchi, Takeshi ;

Kida, Daihei ;

Hirano, Yuji ;

Fujibayashi, Takayoshi ;

Sugiura, Fumiaki ;

Hayashi, Masatoshi ;

Funahashi, Koji ;

Hanabayashi, Masahiro ;

Asai, Shuji ;

Ishiguro, Naoki ;

Kojima, Toshihisa .

CLINICAL RHEUMATOLOGY, 2014, 33 (09) :1247-1254

[35] Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies [J].

Shinya Hirabara ;

Nobunori Takahashi ;

Naoki Fukaya ;

Hiroyuki Miyake ;

Yuichiro Yabe ;

Atsushi Kaneko ;

Takayasu Ito ;

Takeshi Oguchi ;

Daihei Kida ;

Yuji Hirano ;

Takayoshi Fujibayashi ;

Fumiaki Sugiura ;

Masatoshi Hayashi ;

Koji Funahashi ;

Masahiro Hanabayashi ;

Shuji Asai ;

Naoki Ishiguro ;

Toshihisa Kojima .

Clinical Rheumatology, 2014, 33 :1247-1254

[36] Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study [J].

D'Agostino, Maria-Antonietta ;

Wakefield, Richard J. ;

Berner-Hammer, Hilde ;

Vittecoq, Olivier ;

Filippou, Georgios ;

Balint, Peter ;

Moeller, Ingrid ;

Iagnocco, Annamaria ;

Naredo, Esperanza ;

Ostergaard, Mikkel ;

Boers, Maarten ;

Gaillez, Corine ;

Van Holder, Karina ;

Le Bars, Manuela .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) :1763-1769

[37] Abatacept inhibits structural damage progression, as assessed by the genant-modified sharp scoring system, in Rheumatoid Arthritis (RA) patients with an inadequate response to Methotrexate (MTX): The aim (abatacept in inadequate responders to MTX) trial - A sub-analysis by disease duration [J].

Emery, P. ;

Westhovens, R. ;

Russell, A. ;

Moreland, L. ;

Kremer, J. ;

Becker, J-C. ;

Teng, J. ;

Genant, H. K. .

RHEUMATOLOGY, 2006, 45 :I41-I42

[38] Abatacept provides significant and sustained benefits in clinical and patient reported outcomes through 2 yrs in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX): The long-term extension (LTE) of the aim trial [J].

Kremer, J. M. ;

Emery, P. ;

Becker, J. P. ;

Aranda, R. ;

Teng, J. ;

Li, T. ;

Westhovens, R. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 :327-327

[39] Sustained remission and major clinical response at 2 years shown with abatacept (CTLA4Ig) in combination with methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. [J].

Dougados, M ;

Westhovens, R ;

St Clair, EW ;

Aranda, R ;

Nuamah, I ;

Zhou, Y ;

Vratsanos, G ;

Becker, JC .

ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :S185-S185

[40] Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment [J].

Russell, A. S. ;

Wallenstein, G. V. ;

Li, T. ;

Martin, M. C. ;

Maclean, R. ;

Blaisdell, B. ;

Gajria, K. ;

Cole, J. C. ;

Becker, J-C ;

Emery, P. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (02) :189-194

← 1 2 3 4 5 →